Baker Biotech Capital (GP), LLC Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Baker Biotech Capital (GP), LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Baker Biotech Capital (GP), LLC. Baker Biotech Capital (GP), LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in NEUROGEN CORP ($NRGN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and 10% Owner in PHARMACYCLICS INC ($PCYC) and 10% Owner in VIROPHARMA INC ($VPHM) and 10% Owner in ADOLOR CORP ($ADLR) and 10% Owner in ALLOS THERAPEUTICS INC ($ALTH) and 10% Owner in Ardea Biosciences, Inc./DE ($IBPI) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in AUXILIUM PHARMACEUTICALS INC ($AUXL).
Latest Insider Trading Transactions of Baker Biotech Capital (GP), LLC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADLR, ALTH, IBPI, AUXL, BCRX, GHDX, IDRA, INCY, NRGN, PCYC, SGEN, VPHM
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 24 2011 | PCYC | PHARMACYCLICS INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 9.93 | 8,987 | 89,219 | 41,519 | 32.5 K to 41.5 K (+27.63 %) |
| Aug 24 2011 | PCYC | PHARMACYCLICS INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 9.97 | 29,956 | 298,640 | 32,532 | 2.6 K to 32.5 K (+1,162.89 %) |
| Aug 24 2011 | PCYC | PHARMACYCLICS INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 10.00 | 767 | 7,669 | 2,576 | 1.8 K to 2.6 K (+42.40 %) |
| Aug 03 2011 | AUXL | AUXILIUM PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 17.25 | 6,361 | 109,715 | 844,839 | 851.2 K to 844.8 K (-0.75 %) |
| Aug 03 2011 | AUXL | AUXILIUM PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 18.04 | 61,519 | 1,109,735 | 851,200 | 912.7 K to 851.2 K (-6.74 %) |
| Aug 03 2011 | AUXL | AUXILIUM PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 18.03 | 40,690 | 733,620 | 912,719 | 953.4 K to 912.7 K (-4.27 %) |
| May 13 2011 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | J | 0.00 | 522,800 | 0 | 1,765,213 | 2.3 M to 1.8 M (-22.85 %) |
| Oct 29 2010 | ADLR | ADOLOR CORP | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 1.18 | 376 | 445 | 79,054 | 79.4 K to 79.1 K (-0.47 %) |
| Oct 29 2010 | ADLR | ADOLOR CORP | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 1.19 | 885 | 1,052 | 79,430 | 80.3 K to 79.4 K (-1.10 %) |
| Oct 29 2010 | ADLR | ADOLOR CORP | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 1.30 | 569 | 740 | 80,315 | 80.9 K to 80.3 K (-0.70 %) |
| Oct 29 2010 | ADLR | ADOLOR CORP | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 1.28 | 233 | 298 | 80,884 | 81.1 K to 80.9 K (-0.29 %) |
| Sep 23 2010 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 14.86 | 70,150 | 1,042,485 | 2,933,021 | 3 M to 2.9 M (-2.34 %) |
| Sep 23 2010 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 14.71 | 88,670 | 1,304,495 | 3,003,171 | 3.1 M to 3 M (-2.87 %) |
| Sep 23 2010 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 14.94 | 238,230 | 3,559,871 | 3,091,841 | 3.3 M to 3.1 M (-7.15 %) |
| Aug 11 2010 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 14.00 | 22,751 | 318,468 | 3,330,071 | 3.4 M to 3.3 M (-0.68 %) |
| Aug 11 2010 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 14.00 | 11,711 | 163,953 | 3,352,822 | 3.4 M to 3.4 M (-0.35 %) |
| Aug 11 2010 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 14.08 | 74,201 | 1,044,847 | 3,364,533 | 3.4 M to 3.4 M (-2.16 %) |
| Aug 11 2010 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Sell | S | 14.09 | 48,266 | 679,938 | 3,438,734 | 3.5 M to 3.4 M (-1.38 %) |
| May 10 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 12.70 | 463,082 | 5,881,836 | 2,288,013 | 2.8 M to 2.3 M (-16.83 %) |
| May 10 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 12.46 | 97,940 | 1,220,176 | 2,751,095 | 2.8 M to 2.8 M (-3.44 %) |
| May 10 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 12.62 | 62,658 | 791,026 | 2,849,035 | 2.9 M to 2.8 M (-2.15 %) |
| May 10 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 12.65 | 224,106 | 2,834,381 | 2,911,693 | 3.1 M to 2.9 M (-7.15 %) |
| May 04 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 12.78 | 134,727 | 1,721,286 | 3,135,799 | 3 M to 3.1 M (+4.49 %) |
| May 04 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 12.76 | 263,216 | 3,358,557 | 3,001,072 | 2.7 M to 3 M (+9.61 %) |
| May 04 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 12.98 | 225,068 | 2,921,518 | 2,737,856 | 2.5 M to 2.7 M (+8.96 %) |
| May 04 2010 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 13.03 | 618,993 | 8,066,036 | 2,512,788 | 1.9 M to 2.5 M (+32.69 %) |
| May 04 2010 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.75 | 273,404 | 2,939,093 | 4,626,213 | 4.4 M to 4.6 M (+6.28 %) |
| Aug 17 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.60 | 343 | 6,723 | 1,253,653 | 1.3 M to 1.3 M (+0.03 %) |
| Aug 17 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.99 | 11,314 | 226,162 | 1,253,310 | 1.2 M to 1.3 M (+0.91 %) |
| Aug 12 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.70 | 4,690 | 92,378 | 1,241,996 | 1.2 M to 1.2 M (+0.38 %) |
| Aug 12 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.36 | 1,858 | 35,968 | 1,237,306 | 1.2 M to 1.2 M (+0.15 %) |
| Aug 12 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.47 | 44 | 857 | 1,235,448 | 1.2 M to 1.2 M (0.00 %) |
| Aug 12 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.37 | 5,623 | 108,893 | 1,235,404 | 1.2 M to 1.2 M (+0.46 %) |
| Aug 12 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.48 | 1,454 | 28,323 | 1,229,781 | 1.2 M to 1.2 M (+0.12 %) |
| Aug 12 2009 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.50 | 2,208 | 43,055 | 1,228,327 | 1.2 M to 1.2 M (+0.18 %) |
| May 20 2009 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.72 | 378,053 | 3,674,675 | 4,352,809 | 4 M to 4.4 M (+9.51 %) |
| Jun 01 2009 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 3.89 | 19,585 | 76,088 | 1,522,015 | 1.5 M to 1.5 M (-1.27 %) |
| Jun 01 2009 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 3.86 | 50,574 | 195,423 | 1,541,600 | 1.6 M to 1.5 M (-3.18 %) |
| Jun 01 2009 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 4.12 | 48,438 | 199,700 | 1,592,174 | 1.6 M to 1.6 M (-2.95 %) |
| Jun 01 2009 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 4.30 | 9,409 | 40,471 | 1,640,612 | 1.7 M to 1.6 M (-0.57 %) |
| Jun 01 2009 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 4.50 | 69,762 | 314,215 | 1,650,021 | 1.7 M to 1.7 M (-4.06 %) |
| Jun 01 2009 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 4.45 | 38,710 | 172,395 | 1,719,783 | 1.8 M to 1.7 M (-2.20 %) |
| Mar 05 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 485,000 | 5,440,973 | 3,597,000 | |
| Mar 05 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 388,000 | 4,352,778 | 15,055,000 | |
| Mar 05 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 182,000 | 2,041,767 | 14,667,000 | |
| Mar 05 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 546,000 | 6,125,301 | 14,485,000 | |
| Mar 05 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 2.16 | 1,248 | 2,693 | 3,487,000 | 3.5 M to 3.5 M (+0.04 %) |
| Mar 05 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 2.14 | 2,199 | 4,709 | 3,485,752 | 3.5 M to 3.5 M (+0.06 %) |
| Mar 02 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 1,818,000 | 20,395,233 | 13,939,000 | |
| Mar 02 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 454,000 | 5,093,199 | 12,121,000 | |
| Mar 02 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 691,000 | 7,751,984 | 11,667,000 | |
| Mar 02 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 1,761,000 | 19,755,779 | 10,976,000 | |
| Mar 02 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 2.17 | 3,682 | 7,993 | 3,483,553 | 3.5 M to 3.5 M (+0.11 %) |
| Mar 02 2009 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 2.14 | 4,019 | 8,587 | 3,479,871 | 3.5 M to 3.5 M (+0.12 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.26 | 235 | 1,940 | 2,022,293 | 2 M to 2 M (-0.01 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.17 | 263,312 | 2,152,260 | 2,022,528 | 2.3 M to 2 M (-11.52 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.11 | 50,041 | 405,617 | 2,285,840 | 2.3 M to 2.3 M (-2.14 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.17 | 12,713 | 103,882 | 2,335,881 | 2.3 M to 2.3 M (-0.54 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.16 | 67,709 | 552,729 | 2,348,594 | 2.4 M to 2.3 M (-2.80 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.46 | 256,936 | 2,173,524 | 2,416,303 | 2.7 M to 2.4 M (-9.61 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.47 | 27,485 | 232,781 | 2,373,239 | 2.4 M to 2.4 M (-1.14 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 9.03 | 2,859 | 25,823 | 2,700,724 | 2.7 M to 2.7 M (-0.11 %) |
| Feb 06 2009 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 8.01 | 100,309 | 803,104 | 2,703,583 | 2.8 M to 2.7 M (-3.58 %) |
| Oct 21 2008 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | J | 2.74 | 4,107 | 11,253 | 2,208,355 | 2.2 M to 2.2 M (+0.19 %) |
| Nov 13 2008 | NRGN | NEUROGEN CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | C | 0.00 | 50,175 | 0 | 0 | |
| Nov 13 2008 | NRGN | NEUROGEN CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | C | 0.00 | 1,304,550 | 0 | 3,500,059 | 2.2 M to 3.5 M (+59.42 %) |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 1,422,000 | 15,954,840 | 9,215,000 | |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 11.22 | 2,383,000 | 26,737,260 | 2,383,000 | |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 3.60 | 75,808 | 272,560 | 3,475,840 | 3.4 M to 3.5 M (+2.23 %) |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 3.62 | 13,433 | 48,594 | 3,400,032 | 3.4 M to 3.4 M (+0.40 %) |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 3.56 | 64,559 | 230,043 | 3,386,599 | 3.3 M to 3.4 M (+1.94 %) |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 3.60 | 3,904 | 14,041 | 3,322,040 | 3.3 M to 3.3 M (+0.12 %) |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 3.33 | 41,510 | 138,303 | 3,318,136 | 3.3 M to 3.3 M (+1.27 %) |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 3.33 | 25,153 | 83,865 | 3,276,626 | 3.3 M to 3.3 M (+0.77 %) |
| Dec 19 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 3.15 | 2,903 | 9,144 | 3,251,473 | 3.2 M to 3.3 M (+0.09 %) |
| Nov 24 2008 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 0.98 | 2,339 | 2,287 | 1,758,493 | 1.8 M to 1.8 M (+0.13 %) |
| Nov 24 2008 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 0.91 | 9,831 | 8,987 | 1,756,154 | 1.7 M to 1.8 M (+0.56 %) |
| Nov 24 2008 | BCRX | BIOCRYST PHARMACEU ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 1.00 | 96,033 | 96,033 | 1,746,323 | 1.7 M to 1.7 M (+5.82 %) |
| Dec 19 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Option Exercise | P | 11.14 | 46,195 | 514,612 | 46,195 | |
| Dec 19 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 11.14 | 184,780 | 2,058,449 | 1,646,964 | 1.5 M to 1.6 M (+12.64 %) |
| Dec 19 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Option Exercise | P | 11.14 | 46,195 | 514,612 | 46,195 | |
| Dec 19 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 11.14 | 184,780 | 2,058,449 | 1,646,964 | 1.5 M to 1.6 M (+12.64 %) |
| Aug 05 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.00 | 201,648 | 1,814,832 | 3,248,570 | 3 M to 3.2 M (+6.62 %) |
| Jul 30 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 14.93 | 9,839 | 146,906 | 209,110 | 218.9 K to 209.1 K (-4.49 %) |
| Jul 30 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 14.87 | 2,952 | 43,904 | 218,949 | 221.9 K to 218.9 K (-1.33 %) |
| Jul 25 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 15.01 | 9,224 | 138,468 | 221,901 | 231.1 K to 221.9 K (-3.99 %) |
| Jul 25 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 15.02 | 15,374 | 230,933 | 231,125 | 246.5 K to 231.1 K (-6.24 %) |
| Jul 25 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 14.86 | 9,839 | 146,198 | 246,499 | 256.3 K to 246.5 K (-3.84 %) |
| Jul 21 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 14.80 | 18,449 | 273,045 | 256,338 | 274.8 K to 256.3 K (-6.71 %) |
| Jul 16 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 15.24 | 8,579 | 130,754 | 274,787 | 283.4 K to 274.8 K (-3.03 %) |
| Jul 01 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 14.51 | 4,920 | 71,406 | 283,366 | 288.3 K to 283.4 K (-1.71 %) |
| Jul 01 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 14.99 | 12,606 | 188,998 | 288,286 | 300.9 K to 288.3 K (-4.19 %) |
| Jul 01 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 15.41 | 165,874 | 2,556,118 | 300,892 | 466.8 K to 300.9 K (-35.54 %) |
| Apr 15 2008 | NRGN | NEUROGEN CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 2.30 | 50,175 | 115,403 | 50,175 | |
| Apr 15 2008 | NRGN | NEUROGEN CORP | Baker Biotech Capital (GP), LL ... | Director | Option Exercise | P | 0.00 | 50,175 | 0 | 50,175 | |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.64 | 131 | 2,573 | 1,226,119 | 1.2 M to 1.2 M (+0.01 %) |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.61 | 168 | 3,295 | 1,225,988 | 1.2 M to 1.2 M (+0.01 %) |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.66 | 6,849 | 134,628 | 1,225,820 | 1.2 M to 1.2 M (+0.56 %) |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.67 | 8,271 | 162,653 | 1,218,971 | 1.2 M to 1.2 M (+0.68 %) |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 20.21 | 36,554 | 738,742 | 1,210,700 | 1.2 M to 1.2 M (+3.11 %) |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 20.01 | 1,103 | 22,071 | 1,174,146 | 1.2 M to 1.2 M (+0.09 %) |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.61 | 22,883 | 448,697 | 1,173,043 | 1.2 M to 1.2 M (+1.99 %) |
| Jun 09 2008 | GHDX | GENOMIC HEALTH INC | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 19.50 | 56 | 1,092 | 1,150,160 | 1.2 M to 1.2 M (0.00 %) |
| May 16 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Option Exercise | C | 0.00 | 56 | 0 | 0 | |
| May 16 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | C | 0.00 | 294,624 | 0 | 1,462,184 | 1.2 M to 1.5 M (+25.23 %) |
| Apr 21 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 13.28 | 11,044 | 146,664 | 1,167,560 | 1.2 M to 1.2 M (+0.95 %) |
| Apr 08 2008 | IBPI | Ardea Biosciences, ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 13.28 | 76,141 | 1,011,152 | 1,156,516 | 1.1 M to 1.2 M (+7.05 %) |
| May 27 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.64 | 316,754 | 1,786,493 | 2,803,892 | 2.5 M to 2.8 M (+12.74 %) |
| Mar 17 2008 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 8.14 | 1,927 | 15,678 | 2,204,248 | 2.2 M to 2.2 M (+0.09 %) |
| Mar 17 2008 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 8.67 | 1,326 | 11,491 | 2,202,321 | 2.2 M to 2.2 M (+0.06 %) |
| Mar 17 2008 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 8.69 | 18,792 | 163,349 | 2,200,995 | 2.2 M to 2.2 M (+0.86 %) |
| Jan 10 2008 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 8.95 | 27,828 | 249,013 | 2,182,203 | 2.2 M to 2.2 M (+1.29 %) |
| Jan 10 2008 | VPHM | VIROPHARMA INC | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 8.76 | 40,716 | 356,538 | 2,154,375 | 2.1 M to 2.2 M (+1.93 %) |
| Mar 19 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.02 | 17,793 | 142,732 | 3,974,756 | 4 M to 4 M (+0.45 %) |
| Mar 19 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 7.80 | 23,873 | 186,231 | 3,956,963 | 3.9 M to 4 M (+0.61 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.06 | 14,740 | 118,738 | 3,933,090 | 3.9 M to 3.9 M (+0.38 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.08 | 31,566 | 255,161 | 3,918,350 | 3.9 M to 3.9 M (+0.81 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 7.93 | 14,396 | 114,090 | 3,886,784 | 3.9 M to 3.9 M (+0.37 %) |
| Mar 14 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 7.98 | 4,302 | 34,337 | 3,872,388 | 3.9 M to 3.9 M (+0.11 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.06 | 8,601 | 77,885 | 3,868,086 | 3.9 M to 3.9 M (+0.22 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.94 | 346 | 3,093 | 3,859,485 | 3.9 M to 3.9 M (+0.01 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.00 | 19,896 | 179,112 | 3,859,139 | 3.8 M to 3.9 M (+0.52 %) |
| Feb 11 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.00 | 5,810 | 52,287 | 3,839,243 | 3.8 M to 3.8 M (+0.15 %) |
| Jan 23 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 8.78 | 18,869 | 165,623 | 3,833,433 | 3.8 M to 3.8 M (+0.49 %) |
| Jan 23 2008 | SGEN | SEATTLE GENETICS I ... | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.00 | 560,047 | 5,040,423 | 3,814,564 | 3.3 M to 3.8 M (+17.21 %) |
| Jan 24 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.62 | 65 | 690 | 3,046,922 | 3 M to 3 M (0.00 %) |
| Jan 16 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.99 | 13,675 | 150,254 | 3,046,857 | 3 M to 3 M (+0.45 %) |
| Jan 11 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.94 | 12,120 | 132,548 | 3,033,182 | 3 M to 3 M (+0.40 %) |
| Jan 11 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 11.01 | 490 | 5,392 | 3,021,062 | 3 M to 3 M (+0.02 %) |
| Jan 11 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.94 | 35,783 | 391,566 | 3,020,572 | 3 M to 3 M (+1.20 %) |
| Jan 08 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.00 | 9,541 | 95,368 | 2,984,789 | 3 M to 3 M (+0.32 %) |
| Jan 08 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 10.89 | 181,168 | 1,973,644 | 2,975,248 | 2.8 M to 3 M (+6.48 %) |
| Jan 08 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.48 | 83,853 | 795,019 | 2,794,080 | 2.7 M to 2.8 M (+3.09 %) |
| Jan 08 2008 | INCY | INCYTE CORP | Baker Biotech Capital (GP), LL ... | Director | Buy | P | 9.47 | 118,009 | 1,117,144 | 2,710,227 | 2.6 M to 2.7 M (+4.55 %) |
| Jan 14 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 13.00 | 215 | 2,796 | 466,766 | 467 K to 466.8 K (-0.05 %) |
| Jan 09 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 13.00 | 1,107 | 14,392 | 466,981 | 468.1 K to 467 K (-0.24 %) |
| Jan 09 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 13.00 | 31 | 403 | 468,088 | 468.1 K to 468.1 K (-0.01 %) |
| Jan 09 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 13.00 | 31 | 403 | 468,119 | 468.2 K to 468.1 K (-0.01 %) |
| Jan 04 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 13.14 | 5,380 | 70,709 | 468,150 | 473.5 K to 468.2 K (-1.14 %) |
| Jan 04 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 13.29 | 5,166 | 68,668 | 473,530 | 478.7 K to 473.5 K (-1.08 %) |
| Jan 04 2008 | IDRA | IDERA PHARMACEUTIC ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Sell | S | 12.94 | 15,374 | 198,989 | 478,696 | 494.1 K to 478.7 K (-3.11 %) |
| Feb 27 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.00 | 11,730 | 70,380 | 2,487,138 | 2.5 M to 2.5 M (+0.47 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.20 | 8,211 | 50,908 | 2,475,408 | 2.5 M to 2.5 M (+0.33 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 5.90 | 8,797 | 51,902 | 2,467,197 | 2.5 M to 2.5 M (+0.36 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.50 | 8,940 | 58,105 | 2,458,400 | 2.4 M to 2.5 M (+0.36 %) |
| Feb 21 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.75 | 8,862 | 59,850 | 2,449,460 | 2.4 M to 2.4 M (+0.36 %) |
| Jan 23 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 6.92 | 161 | 1,113 | 2,440,598 | 2.4 M to 2.4 M (+0.01 %) |
| Jan 23 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.15 | 1,246 | 8,913 | 2,440,437 | 2.4 M to 2.4 M (+0.05 %) |
| Jan 23 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.22 | 1,430 | 10,318 | 2,439,191 | 2.4 M to 2.4 M (+0.06 %) |
| Jan 17 2008 | ALTH | ALLOS THERAPEUTICS ... | Baker Biotech Capital (GP), LL ... | 10% Owner | Buy | P | 7.50 | 5,600 | 42,000 | 2,437,761 | 2.4 M to 2.4 M (+0.23 %) |